Antibacterial Hemostatic Dressing-Stop Bleeding & Prevent Bacterial Infection



Technology

Nanotechnology-based patented formulation (Indian Patent App. No 201711044089, Indian Patent No 346127)


- * Hemostatic product is designed for rapid bleeding arrest, prevents bacterial infection and reduce the cytotoxicity and immunogenic response.
- **Features:** High fluid absorption capacity, Faster clotting efficiency, High mechanical strength, Exhibit broad-spectrum antibacterial properties, Non-irritant and compatibility with the body's natural process, minimizing adverse reactions.
- * Mechanism: Large fluid uptake capacity and adhesion of RBCs due to charge-based interaction.

Technology Readiness Level (TRL): 4

Market Size of Hemostatic Dressing and Opportunity

Hemostatic Wound Dressing market was USD 415 million in 2022, and expected reach up to USD 740 million by 2030. Growing demand for emergency medical care, the indigenously developed patented nanocomposite hemostatic dressing has substantial opportunity for market penetration.

Hemostatic Wound Dressing Market Analysis




Regulatory clearance

Preclinical biocompatibility studies (ISO 10993) under GLP is ongoing

End-user


Hospitals, Emergency response units, Military medical services.



Efficacy study

The microporous structure helps to absorb large amount of blood and plasma

Doesn't elicit inflammatory cytokines level



Kills 99.99% broad spectrum microorganisms through contact killing mode

(s) 400 - 40

Stops bleeding within a few minutes

Antibacterial Hemostatic Dressing

Stop Bleeding & Prevent Bacterial Infection



- Nanotechnology based proprietary blend (Indian Patent App. No 201711044089, Indian Patent No 346127) of biocompatible chitosan and graphene nanocomposite material with inherent hemostatic properties.
- ❖ New generation hemostatic dressing is designed for rapid bleeding arrest, and prevents bacterial infection. It is a single-use hemostatic wound dressing applied externally with mechanical compression to stop bleeding.
- ❖ Features: High fluid absorption capacity, Faster clotting efficiency, High mechanical strength, Soft & flexible, Exhibit broad-spectrum antibacterial properties, Non-irritant & compatible with body's natural process, Minimizing adverse reactions, Easy application.

Technology Readiness Level (TRL): 4

Regulatory clearance

Preclinical biocompatibility studies under GLP is ongoing

Versatile Application

Bleeding control in

- Lacerations
- Punctures
- Abrasions
- Surgical wounds (operative, postoperative, dermatological)
- Traumatic injuries




Market Size of Hemostatic Dressing and Opportunity


Hemostatic Wound Dressing market was USD 415 million in 2022, and expected reach up to USD 740 million by 2030. Growing demand for emergency medical care, the indigenously developed patented nanocomposite hemostatic dressing has substantial opportunity for market penetration.

End-user


Home & Family
Sports & Outdoor Activities
Medical & Healthcare
Tactical & Defense




High absorbency




The microporous structure helps to absorb large amount of blood and plasma










Stops bleeding within a few minutes


Anti-inflammatory activity



Inflammatory cytokines (IL-6 and TNF- α) level in the control and nanocomposite dressing treated macrophage cells

Blood Clotting Mechanism

Compression and vasoconstriction
Charge based interaction
Plasma absorption
Platelet aggregation and activation
Clotting cascade amplification



The underlying mechanisms of rapid hemostatic properties include compression, charge based interaction with red blood cells, activation of platelets, amplification of the intrinsic and extrinsic coagulation cascade, and fibrin clot formation. Chitosan and graphene nanocomposite material contribute synergistically to accelerate the blood clotting at the bleeding surface.

Preclinical Biosafety (ISO 10993)* & Efficacy studies

- ✓ Cytotoxicity study completed
- ✓ Hemocompatibility study completed
- ✓ Acute and Sub-acute toxicity study completed
- ✓ Skin irritation study completed
- ✓ Biodegradation study completed
- In-vivo hemostatic efficacy conducted on Wister rat and Rabbit *Non GLP studies